Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters

Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters

Marcin Pasiarski,1,2 Barbara Sosnowska-Pasiarska,3 Ewelina Grywalska,4,5 Agnieszka Stelmach-Gołdyś,1 Artur Kowalik,6 Stanisław Góźdź,2,7 Jacek Roliński4,5 1Department of Hematology, Holycross Cancer Center, Kielce, Poland; 2Department of Immunology, Faculty of Health Sciences, Jan Kochano...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pasiarski M, Sosnowska-Pasiarska B, Grywalska E, Stelmach-Gołdyś A, Kowalik A, Góźdź S, Roliński J
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
13-valent pneumococcal conjugate vaccine
immune response
monoclonal gammopathy of undetermined significance
M protein
plasmablasts
pneumococcal antibodies
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/5e1337339c0d41e883e1e6f39955b0ea
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:5e1337339c0d41e883e1e6f39955b0ea
record_format dspace
spelling oai:doaj.org-article:5e1337339c0d41e883e1e6f39955b0ea2021-12-02T09:08:06ZImmunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters1178-1998https://doaj.org/article/5e1337339c0d41e883e1e6f39955b0ea2019-10-01T00:00:00Zhttps://www.dovepress.com/immunogenicity-and-safety-of-the-13-valent-pneumococcal-conjugate-vacc-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Marcin Pasiarski,1,2 Barbara Sosnowska-Pasiarska,3 Ewelina Grywalska,4,5 Agnieszka Stelmach-Gołdyś,1 Artur Kowalik,6 Stanisław Góźdź,2,7 Jacek Roliński4,5 1Department of Hematology, Holycross Cancer Center, Kielce, Poland; 2Department of Immunology, Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland; 3Department of Oncocardiology, Holycross Cancer Center, Kielce, Poland; 4Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, Poland; 5Clinical Immunology Department, St. John’s Cancer Center, Lublin, Poland; 6Department of Molecular Diagnostics, Holycross Cancer Center, Kielce, Poland; 7Department of Oncology, Holycross Cancer Center, Kielce, PolandCorrespondence: Ewelina GrywalskaDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, Chodzki 4a, Lublin 20-093, PolandTel +48 81 448 6420Fax +48 81 448 6421Email ewelina.grywalska@gmail.comPurpose: Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing infections. Streptococcus pneumoniae vaccinations are recommended for immunocompromised patients, including patients with lymphoproliferative disorders such as MGUS. The objective of the study was to assess the immune response to the 13-valent pneumococcal conjugate vaccine (PCV13) in treatment-naive MGUS patients versus healthy subjects. All study groups were evaluated for the levels of specific pneumococcal antibodies, the levels of IgG and IgG subclasses, and selected peripheral blood lymphocyte subpopulations, including the proportion of plasmablasts before and after immunization.Patients and methods: A total of 22 previously untreated patients with MGUS and 15 healthy age- and sex-matched volunteers were included in the study. All participants were immunized with PCV13 Prevenar13 (Pfizer). The following parameters were assessed: 1) serum-specific pneumococcal antibody titers before and 30 days after vaccination, 2) percentage of plasmablasts, defined as CD19+/IgD−/CD27++, before and 7 days after vaccination, 3) serum total IgG and IgG1, IgG2, IgG3, IgG4 levels before and 30 days after vaccination.Results and conclusion: PCV13 vaccination in MGUS patients is safe and effectively protects against S. pneumoniae infection. In unvaccinated individuals, vaccination should be carried out as soon as possible after diagnosis. It can protect patients against serious infectious complications, which can contribute to extending the time to progression and transformation into more aggressive diseases. PCV13 vaccination is more effective in MGUS patients with a lower concentration of M protein. Serum M protein concentration in patients diagnosed with MGUS may be a useful predictor of the effectiveness of vaccination.Keywords: 13-valent pneumococcal conjugate vaccine, immune response, monoclonal gammopathy of undetermined significance, M protein, plasmablasts, pneumococcal antibodiesPasiarski MSosnowska-Pasiarska BGrywalska EStelmach-Gołdyś AKowalik AGóźdź SRoliński JDove Medical Pressarticle13-valent pneumococcal conjugate vaccineimmune responsemonoclonal gammopathy of undetermined significanceM proteinplasmablastspneumococcal antibodiesGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 14, Pp 1741-1749 (2019)
institution DOAJ
collection DOAJ
language EN
topic 13-valent pneumococcal conjugate vaccine
immune response
monoclonal gammopathy of undetermined significance
M protein
plasmablasts
pneumococcal antibodies
Geriatrics
RC952-954.6
spellingShingle 13-valent pneumococcal conjugate vaccine
immune response
monoclonal gammopathy of undetermined significance
M protein
plasmablasts
pneumococcal antibodies
Geriatrics
RC952-954.6
Pasiarski M
Sosnowska-Pasiarska B
Grywalska E
Stelmach-Gołdyś A
Kowalik A
Góźdź S
Roliński J
Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
description Marcin Pasiarski,1,2 Barbara Sosnowska-Pasiarska,3 Ewelina Grywalska,4,5 Agnieszka Stelmach-Gołdyś,1 Artur Kowalik,6 Stanisław Góźdź,2,7 Jacek Roliński4,5 1Department of Hematology, Holycross Cancer Center, Kielce, Poland; 2Department of Immunology, Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland; 3Department of Oncocardiology, Holycross Cancer Center, Kielce, Poland; 4Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, Poland; 5Clinical Immunology Department, St. John’s Cancer Center, Lublin, Poland; 6Department of Molecular Diagnostics, Holycross Cancer Center, Kielce, Poland; 7Department of Oncology, Holycross Cancer Center, Kielce, PolandCorrespondence: Ewelina GrywalskaDepartment of Clinical Immunology and Immunotherapy, Medical University of Lublin, Chodzki 4a, Lublin 20-093, PolandTel +48 81 448 6420Fax +48 81 448 6421Email ewelina.grywalska@gmail.comPurpose: Patients with monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of developing infections. Streptococcus pneumoniae vaccinations are recommended for immunocompromised patients, including patients with lymphoproliferative disorders such as MGUS. The objective of the study was to assess the immune response to the 13-valent pneumococcal conjugate vaccine (PCV13) in treatment-naive MGUS patients versus healthy subjects. All study groups were evaluated for the levels of specific pneumococcal antibodies, the levels of IgG and IgG subclasses, and selected peripheral blood lymphocyte subpopulations, including the proportion of plasmablasts before and after immunization.Patients and methods: A total of 22 previously untreated patients with MGUS and 15 healthy age- and sex-matched volunteers were included in the study. All participants were immunized with PCV13 Prevenar13 (Pfizer). The following parameters were assessed: 1) serum-specific pneumococcal antibody titers before and 30 days after vaccination, 2) percentage of plasmablasts, defined as CD19+/IgD−/CD27++, before and 7 days after vaccination, 3) serum total IgG and IgG1, IgG2, IgG3, IgG4 levels before and 30 days after vaccination.Results and conclusion: PCV13 vaccination in MGUS patients is safe and effectively protects against S. pneumoniae infection. In unvaccinated individuals, vaccination should be carried out as soon as possible after diagnosis. It can protect patients against serious infectious complications, which can contribute to extending the time to progression and transformation into more aggressive diseases. PCV13 vaccination is more effective in MGUS patients with a lower concentration of M protein. Serum M protein concentration in patients diagnosed with MGUS may be a useful predictor of the effectiveness of vaccination.Keywords: 13-valent pneumococcal conjugate vaccine, immune response, monoclonal gammopathy of undetermined significance, M protein, plasmablasts, pneumococcal antibodies
format article
author Pasiarski M
Sosnowska-Pasiarska B
Grywalska E
Stelmach-Gołdyś A
Kowalik A
Góźdź S
Roliński J
author_facet Pasiarski M
Sosnowska-Pasiarska B
Grywalska E
Stelmach-Gołdyś A
Kowalik A
Góźdź S
Roliński J
author_sort Pasiarski M
title Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
title_short Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
title_full Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
title_fullStr Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
title_full_unstemmed Immunogenicity And Safety Of The 13-Valent Pneumococcal Conjugate Vaccine In Patients With Monoclonal Gammopathy Of Undetermined Significance – Relationship With Selected Immune And Clinical Parameters
title_sort immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with monoclonal gammopathy of undetermined significance – relationship with selected immune and clinical parameters
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/5e1337339c0d41e883e1e6f39955b0ea
work_keys_str_mv AT pasiarskim immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancendashrelationshipwithselectedimmuneandclinicalparameters
AT sosnowskapasiarskab immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancendashrelationshipwithselectedimmuneandclinicalparameters
AT grywalskae immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancendashrelationshipwithselectedimmuneandclinicalparameters
AT stelmachgołdysa immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancendashrelationshipwithselectedimmuneandclinicalparameters
AT kowalika immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancendashrelationshipwithselectedimmuneandclinicalparameters
AT gozdzs immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancendashrelationshipwithselectedimmuneandclinicalparameters
AT rolinskij immunogenicityandsafetyofthe13valentpneumococcalconjugatevaccineinpatientswithmonoclonalgammopathyofundeterminedsignificancendashrelationshipwithselectedimmuneandclinicalparameters
_version_ 1718398246707003392

Ejemplares similares